Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Employees

272

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	$0.0292	-12.97%	141,196
23/07/26	$0.0336	+17.72%	230,657
22/07/26	$0.0285	-5.00%	55,496
21/07/26	$0.0300	-9.09%	169,124
20/07/26	$0.0330	-16.46%	260,271

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 23:57:00 24/07/2026 +04			5-day change	1st Jan Change
0.0292 ^USD	-12.97%		-26.08%	+12.31%

05-19	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI

Market Cap	7.74M 6.8M 6.32M 5.8M 10.9M 745M 11.07M 75.07M 29.33M 366M 29.05M 28.43M 1.27B	P/E 2024	-1.8x	P/E 2025	0.33x
Enterprise Value	-4.13M -3.63M -3.37M -3.1M -5.82M -398M -5.91M -40.05M -15.65M -196M -15.5M -15.17M -676M	EV / Sales 2024	0.34x	EV / Sales 2025	-0.84x
Free-Float	14.03%	Yield 2024 *	-	Yield 2025	-

05-19	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI
11-17	Adaptimmune Therapeutics plc Announces Leadership Changes	CI
27/10/25	Evaxion Names Helen Tayton-Martin as Chief Executive Officer	MT
27/10/25	Adaptimmune Therapeutics plc(OTCPK:ADAP.Y) dropped from NASDAQ Composite Index	CI
24/10/25	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading	MT
23/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
22/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
21/10/25	European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	MT
20/10/25	Top Midday Decliners	MT
20/10/25	European Equities Close Mostly Higher in Monday Trading; UK Sentiment Sees 'Some of the Gloom Lift'	MT
20/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
20/10/25	Adaptimmune Therapeutics to Voluntarily Delist From Nasdaq	MT

30/07/25	Guggenheim Downgrades Adaptimmune Therapeutics to Neutral From Buy	MT
29/07/25	HC Wainwright Downgrades Adaptimmune Therapeutics to Neutral From Buy	MT
26/06/25	Mizuho Downgrades Adaptimmune Therapeutics to Neutral From Outperform, Cuts Price Target to $0.50 From $1.50 on Solvency Concerns	MT
27/11/24	Mizuho Cuts Price Target on Adaptimmune Therapeutics to $1.50 From $3, Keeps Outperform Rating	MT
30/07/24	HC Wainwright Starts Adaptimmune Therapeutics With Buy Rating, $4 Price Target	MT

Adaptimmune Therapeutics plc Stock

Stocks

ADAPY

US00653A1079

Pharmaceuticals

Valuation: Adaptimmune Therapeutics plc

Chart: Adaptimmune Therapeutics plc

Latest news : Adaptimmune Therapeutics plc

Analysts' recommendations: Adaptimmune Therapeutics plc

Press Releases: Adaptimmune Therapeutics plc

News in other languages: Adaptimmune Therapeutics plc

Quotes and Performance

Course Extremes

Managers and Directors: Adaptimmune Therapeutics plc

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

11-17	Adaptimmune Announces Changes to Board and Executive Leadership Team	NE
20/10/25	Adaptimmune Announces Delisting from Nasdaq	NE
13/08/25	Adaptimmune Reports Q2 Financial Results and Provides Business Update	NE
28/07/25	Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds	NE
13/05/25	Adaptimmune Reports Q1 Financial Results and Provides Business Update	NE

31/05/24	Galapagos gaat samenwerken met Adaptimmune
12/04/24	Roche: Genentech met fin à la collaboration avec Adaptimmune Therapeutics
12/04/24	Roche-Tochter Genentech beendet Zusammenarbeit mit Adaptimmune Therapeutics
11/04/23	GSK : Adaptimmune reprend les droits de deux programmes
07/09/21	Aktien Schweiz Schluss: SMI unter Druck

1 day	-12.97%
1 week	-26.08%
Current month	-20.00%
1 month	-18.89%
3 months	+192.00%
6 months	-16.57%
Current year	+12.31%

1 week	0.02	0.04
1 month	0.02	0.05
Current year	0	0.05
1 year	0	0.28
3 years	0	2.05
5 years	0	6.86
10 years	0	14.62

Manager	Title	Age	Since
Christopher Hill CEO	Chief Executive Officer	46	14/11/2025
Juli P. Miller IRC	Investor Relations Contact	-	01/08/2016
Phil Bassett PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Lawrence Alleva CHM	Chairman	76	14/11/2025
Garry Menzel BRD	Director/Board Member	61	01/06/2023
Christopher Hill BRD	Director/Board Member	46	14/11/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/09/25	Gavin Wood	Sell	Chief Financial Officer	96,000	0.0060%
28/08/25	William Bertrand	Sell	Compliance Officer	207,000	0.0130%
15/08/25	NEA Management Co. LLC	Sell	Company	19,500,000	7.3571%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADAPTIMMUNE THERAPEUTICS PLC	-12.97%	-26.08%	-91.21%	-96.88%	7.74M
REGENERON PHARMACEUTICALS, INC.	+0.63%	-3.06%	+16.18%	-9.78%	66.74B
UCB	+1.23%	+2.80%	+37.51%	+202.14%	53.32B
SAMSUNG BIOLOGICS CO.,LTD.	+10.08%	+51.80%	+51.80%	+51.80%	48.12B
CSL LIMITED	-1.32%	-7.38%	-57.63%	-57.10%	38.25B
BIOGEN INC.	+0.78%	-1.84%	+52.49%	-27.01%	29.85B
INCYTE CORPORATION	+0.84%	+0.36%	+66.93%	+85.42%	23.51B
MODERNA, INC.	-5.17%	-12.54%	+58.98%	-56.04%	21.45B
INNOVENT BIOLOGICS, INC.	-1.21%	+1.12%	+1.98%	+170.93%	19.97B
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	-0.95%	+61.97%	+123.78%	16.38B
Average	-0.14%	-3.50%	+19.90%	+38.73%	31.76B
Weighted average by Cap.	+1.81%	-0.11%	+27.79%	+49.98%

	2024	2025
Net sales	178M 156M 145M 133M 251M 17.14B 255M 1.73B 675M 8.43B 668M 654M 29.14B	5.92M 5.2M 4.84M 4.44M 8.34M 570M 8.47M 57.46M 22.45M 280M 22.24M 21.76M 970M
Net income	-70.81M -62.2M -57.84M -53.08M -99.73M -6.82B -101M -687M -268M -3.35B -266M -260M -11.59B	25.21M 22.14M 20.59M 18.89M 35.5M 2.43B 36.04M 244M 95.52M 1.19B 94.62M 92.58M 4.13B
Net Debt	-77.4M -67.98M -63.22M -58.01M -109M -7.45B -111M -751M -293M -3.66B -291M -284M -12.67B	-11.87M -10.42M -9.69M -8.9M -16.71M -1.14B -16.97M -115M -44.98M -562M -44.56M -43.6M -1.94B